GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » SOC Telemed Inc (NAS:TLMDW) » Definitions » Cash Flow from Financing

SOC Telemed (SOC Telemed) Cash Flow from Financing : $134.26 Mil (TTM As of Dec. 2021)


View and export this data going back to 2020. Start your Free Trial

What is SOC Telemed Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2021, SOC Telemed received $51.55 Mil more from issuing new shares than it paid to buy back shares. It received $82.39 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.32 Mil on other financial activities. In all, SOC Telemed earned $134.26 Mil on financial activities for the six months ended in Dec. 2021.


SOC Telemed Cash Flow from Financing Historical Data

The historical data trend for SOC Telemed's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SOC Telemed Cash Flow from Financing Chart

SOC Telemed Annual Data
Trend Dec19 Dec20 Dec21
Cash Flow from Financing
16.55 63.32 134.26

SOC Telemed Semi-Annual Data
Dec19 Dec20 Dec21
Cash Flow from Financing 16.55 63.32 134.26

SOC Telemed Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

SOC Telemed's Cash from Financing for the fiscal year that ended in Dec. 2021 is calculated as:

SOC Telemed's Cash from Financing for the quarter that ended in Dec. 2021 is:


For stock reported annually, GuruFocus uses latest annual data as the TTM data. Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2021 was $134.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SOC Telemed  (NAS:TLMDW) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

SOC Telemed's issuance of stock for the six months ended in Dec. 2021 was $51.55 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

SOC Telemed's repurchase of stock for the six months ended in Dec. 2021 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

SOC Telemed's net issuance of debt for the six months ended in Dec. 2021 was $82.39 Mil. SOC Telemed received $82.39 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

SOC Telemed's net issuance of preferred for the six months ended in Dec. 2021 was $0.00 Mil. SOC Telemed paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

SOC Telemed's cash flow for dividends for the six months ended in Dec. 2021 was $0.00 Mil. SOC Telemed received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

SOC Telemed's other financing for the six months ended in Dec. 2021 was $0.32 Mil. SOC Telemed received $0.32 Mil on other financial activities.


SOC Telemed Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of SOC Telemed's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


SOC Telemed (SOC Telemed) Business Description

Traded in Other Exchanges
N/A
Address
1768 Business Center Drive, Suite 100, Reston, VA, USA, 20190
SOC Telemed Inc is a provider of acute care telemedicine services and technology to U.S. hospitals and healthcare systems based on number of clients. It provides technology enabled clinical solutions which include acute teleNeurology, telePsychiatry, and teleICU, and telePulmonology service. It supports specialty care, providing time-sensitive specialty care when patients are vulnerable and may not otherwise have access. Its solution was developed to support complex workflows in the acute care setting by integrating cloud-based software platform, Telemed IQ, with a panel of patient advocates and a network of clinical specialists to create a seamless, acute telemedicine solution.
Executives
David R. Fletcher officer: Interim CFO C/O SOC TELEMED, INC., 1768 BUSINESS CENTER DRIVE, SUITE 100, RESTON VA 20190
David Mikula officer: Chief Operating Officer C/O SOC TELEMED, INC. 1768 BUSINESS CENTER DRIVE, SUITE 100 RESTON VA 20190
Gyasi C. Chisley director C/O SOC TELEMED, INC. 1768 BUSINESS CENTER DRIVE, SUITE 100 RESTON VA 20190
Christopher M. Gallagher director C/O SOC TELEMED, INC. 1768 BUSINESS CENTER DRIVE, SUITE 100 RESTON VA 20190
Steven J Shulman director 1564 NE EXPRESSWAY, ATTN: BJ PURCELL, ATLANTA GA 30329
Christopher K Knibb officer: Chief Financial Officer C/O SOC TELEMED, INC. 1768 BUSINESS CENTER DRIVE, SUITE 100 RESTON VA 20190
Warburg Pincus Partners Ii, L.p. director, 10 percent owner 450 LEXINGTON AVENUE, C/O WARBURG PINCUS LLC, NEW YORK NY 10017
Anne Mcgeorge director C/O MAGENTA THERAPEUTICS, INC., 100 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE MA 02139
Wpxi Finance, Lp director, 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Wpxi Gp, L.p. director, 10 percent owner C/O WARBURG PINCUS LLC, 450 LEXINGTON AVE, NEW YORK NY 10017
Warburg Pincus & Co. director, 10 percent owner 450 LEXINGTON AVENUE, NEW YORK, NY NY 100173147
Amr Kronfol director C/O WARBURG PINCUS LLC, 450 LEXINGTON AVE, NEW YORK NY 10017
Joseph P Greskoviak director C/O SOC TELEMED, INC. 1768 BUSINESS CENTER DRIVE, SUITE 100 RESTON VA 20190
Sean Banerjee officer: Chief Technology Officer C/O SOC TELEMED 1768 BUSINESS CENTER DRIVE, SUITE 100 RESTON VA 20190
John W. Kalix director, officer: Chief Executive Officer C/O SOC TELEMED 1768 BUSINESS CENTER DRIVE, SUITE 100 RESTON VA 20190